Together, these results demonstrate the efficacy of the EGFR, Notch and PARP triple-targeting strategy for the treatment of NSCLC tumours, resulting in inhibition of bulk tumour cell growth and reduced tumorigenic cell frequency. The gene discussed is PARP1; the disease is non-small cell lung carcinoma.